{"url_path":"/sec/vor/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1817229/0001193125-26-220689-index.html","accession_number":"0001193125-26-220689","cik":"0001817229","ticker":"VOR","issuer_name":"Vor Biopharma Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1817229/0001193125-26-220689-index.html","primary_entity_key":"0001817229","primary_entity_name":"Vor Biopharma Inc."},"word_count":494,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nIncorporated by Reference\n\nExhibit\n\nNumber\n\n \n\nDescription\n\n \n\nForm\n\n \n\nFile No.\n\n \n\nExhibit Number\n\n \n\nFiling Date\n\n \n\nFiled Herewith\n\n3.1\n\n \n\n[Amended and Restated Certificate of Incorporation of the Registrant](https://www.sec.gov/Archives/edgar/data/1817229/000119312521034387/d117998dex31.htm)\n\n \n\n8-K\n\n \n\n001-39979\n\n \n\n3.1\n\n \n\nFebruary 9, 2021\n\n \n\n \n\n3.2\n\n \n\n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant](https://www.sec.gov/Archives/edgar/data/1817229/000119312525125833/d95113dex31.htm)\n\n \n\n8-K\n\n \n\n001-39979\n\n \n\n3.1\n\n \n\nMay 23, 2025\n\n \n\n \n\n3.3\n\n \n\n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant](https://www.sec.gov/Archives/edgar/data/1817229/000119312525205553/d945826dex31.htm)\n\n \n\n8-K\n\n \n\n001-39979\n\n \n\n3.1\n\n \n\nSeptember 17, 2025\n\n \n\n \n\n3.4\n\n \n\n[Amended and Restated Bylaws of the Registrant](https://www.sec.gov/Archives/edgar/data/1817229/000119312521034387/d117998dex32.htm)\n\n \n\n8-K\n\n \n\n001-39979\n\n \n\n3.2\n\n \n\nFebruary 9, 2021\n\n \n\n \n\n10.1^\n\n \n\n[Securities Purchase Agreement, dated March 26, 2026, by and between the Registrant and the investors named therein](vor-ex10_1.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n \n\n10.2^\n\n \n\n[Registration Rights Agreement, dated March 26, 2026, by and between the Registrant and the investors named therein](vor-ex10_2.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n \n\n10.3+\n\n \n\n[Non-Employee Director Compensation Policy](https://www.sec.gov/Archives/edgar/data/1817229/000119312526130451/vor-ex10_15.htm)\n\n \n\n10-K\n\n \n\n001-39979\n\n \n\n10.15\n\n \n\nMarch 30, 2026\n\n \n\n \n\n31.1\n\n \n\n[Certification of Principal Executive Officer pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](vor-ex31_1.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n31.2\n\n \n\n[Certification of Principal Financial Officer pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](vor-ex31_2.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n32.1†\n\n \n\n[Certification of Principal Executive and Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](vor-ex32_1.htm)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n101.INS\n\n \n\nInline XBRL Instance Document\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema Document\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n101.CAL\n\n \n\nInline XBRL Taxonomy Extension Calculation Linkbase Document\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n66\n\n \n\n101.DEF\n\n \n\n \n\nInline XBRL Taxonomy Extension Definition Linkbase Document\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n101.LAB\n\n \n\n \n\nInline XBRL Taxonomy Extension Label Linkbase Document\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n101.PRE\n\n \n\nInline XBRL Taxonomy Extension Presentation Linkbase Document\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nX\n\n104\n\n \n\nThe cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in Inline XBRL.\n\n \n\n+ Indicates management contract or compensatory plan.\n\n^ Schedules and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant will furnish a supplemental copy of any omitted schedule or similar attachment to the SEC upon request.\n\n† The certifications furnished in Exhibit 32.1 hereto are deemed to be furnished with this Quarterly Report on Form 10-Q and will not be deemed to be “filed” for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Registrant specifically incorporates it by reference.\n\n \n\n \n\n67\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nVOR BIOPHARMA INC.\n\nDate: May 13, 2026\n\nBy:\n\n/s/ Jean-Paul Kress\n\nJean-Paul Kress\n\nPresident and Chief Executive Officer (Principal Executive Officer)\n\n \n\nDate: May 13, 2026\n\nBy:\n\n/s/ Sandesh Mahatme\n\nSandesh Mahatme\n\nChief Financial Officer (Principal Financial Officer and Principal Accounting Officer)\n\n \n\n68"}